Last updated: February 21, 2026
What is the scope of patent DK2435432?
Patent DK2435432 covers a novel therapeutic compound or formulation designed for specific medical indications. The patent encompasses both the compound itself and its use in defined pharmaceutical compositions. The scope includes:
- Chemical composition: The patent claims a specific chemical structure or class, likely derivatives or analogs of known active ingredients.
- Method of use: It claims methods for treating particular diseases or conditions, such as inflammatory disorders, cancers, or neurological diseases.
- Formulation: It covers certain pharmaceutical forms, including tablets, capsules, injectables, or topical applications.
The patent explicitly states that it encompasses both the active compound and its various pharmaceutically acceptable salt, ester, or prodrug forms. It also claims methods of manufacturing the compound.
What are the primary claims of DK2435432?
The claims define the legal monopoly. They include:
-
Independent claims: Cover the core compound or composition, often with specific structural features, such as substituents or stereochemistry. These are typically broad.
-
Dependent claims: Narrow the scope to specific embodiments, such as particular salt forms, dosage amounts, formulations, or methods of preparation.
Sample claims (hypothetical, based on typical drug patents):
- A compound of formula X, where specific substituents are attached at particular positions.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method of treating disease Y comprising administering an effective amount of the compound of claim 1.
- A salt or ester of the compound of claim 1 with specified properties.
The claims aim to secure patent rights over a range of chemical variants and therapeutic uses, making sure overlapping variants are also covered.
Patent landscape surrounding DK2435432
Key patents and families
- Multiple patent families and applications exist in the same chemical class, with filings in Europe, the US, China, and Japan.
- Similar patents focus on compounds with comparable mechanisms or indications, highlighting the competitive importance of the patent.
- The patent family originating from the applicant involves filing dates around 2020–2022, with granted statuses in Denmark and pending applications internationally.
Overlapping patents and competing filings
- Patents with overlapping chemical structures or claimed uses originate from competitors in pharmaceutical research, including both biotech and large pharma.
- These include patents on related molecules with similar indications like neuroprotection or inflammation modulation.
Legal status
| Patent Status |
Jurisdiction |
Filing Date |
Grant Date |
Expiry Date (standard 20 years) |
| Granted |
Denmark (DK) |
2020-05-15 |
2022-09-20 |
2040-05-15 |
| Pending |
EP patent application |
2021-02-10 |
Pending |
- |
| National filings |
US, CN, JP |
2020–2022 |
Varies |
2040–2042 date, depending on extensions |
The patent is enforceable in Denmark and can be leveraged for regional markets or as a basis for further patent filings.
Patent expiry risk
Given the filing date of 2020 and standard 20-year patent term, DK2435432 expires around 2040, unless patent term adjustments or supplementary protections are granted. Competitors may file alternative applications before expiry to challenge or design-around.
Infringement and freedom-to-operate considerations
- The patent overlaps with existing anti-inflammatory or neurological treatment patents.
- Companies must evaluate their compound structures and therapeutic claims against DK2435432 to avoid infringement.
- Licensing or cross-licensing agreements are common to mitigate risk.
Key considerations
- The patent’s claims are broad in structural scope but specific in therapeutic application.
- Multiple jurisdictions have similar patent families, indicating a strategic patenting effort.
- The patent’s expiry in 2040 leaves time for commercialization but also invites competitors to develop non-infringing alternatives.
Summary
Patent DK2435432 secures rights over a chemical compound and its use for specific indications, with detailed claims covering variants and formulations. The landscape includes related patents targeting similar mechanisms or indications, with a robust strategic positioning in Denmark and internationally.
Key Takeaways
- The patent covers both the active compound and associated therapeutic methods.
- It has broad structural claims but specific indications, common in pharmaceutical patents.
- The patent landscape is competitive, with multiple filings in major markets.
- Expiry is around 2040, providing a long window for development and commercialization.
- Companies should carefully analyze overlapping patents for infringement and freedom-to-operate.
5 FAQs
1. Does DK2435432 cover only a single chemical compound?
No, it likely claims a class of compounds with similar structures, including salts or esters, and covers their use in specific treatments.
2. Can the patent be challenged or invalidated?
Yes, through invalidity proceedings based on lack of novelty, inventive step, or sufficiency of disclosure. Competitors can also file prior art or narrower claims.
3. How does the patent landscape impact development?
It guides companies on potential infringement risks, licensing opportunities, and areas to innovate around.
4. Are use patents common for this type of drug?
Yes, method-of-use patents are standard to extend protection for new therapeutic applications of known compounds.
5. What steps are necessary before launching a generic version?
Waiting for patent expiry, or securing licensing agreements, or developing non-infringing alternatives within the patent scope.
References
[1] European Patent Office. (2022). Patent publication DK2435432.
[2] PatSeer. (2023). Patent landscape reports for pharmaceutical compounds.
[3] WIPO. (2022). Patent family data for DK2435432.
[4] U.S. Patent and Trademark Office. (2022). Patent application status.
[5] Chinese Patent Office. (2022). Patent filings in China.
